Member Info for AquaeSulis01

Stuart is not due to deliver anything else in the near future. He has provided a forecast for the launch of skinbiotix as an ingredient being scaled up by Sederma but it is not within his gift to drive the actual launch date.

Wouldn't worry too much re future flipping, pocket money for Croda Int to hoover up the company once they are no longer sat on insider information re the launch date and details

From a skin perspective I do not see the Opti sell as a bad thing because it comes with a 12 mth further lock-in and the security that brings bearing in mind Opti is by far the largest shareholder and now has very sticky hands regarding its remaining shares. From an Opti perspective, in the absence of SOH making a major positive announcement re using the money to grow the business, things are not so rosy. Come the 31st Dec 2021, if there is no significant uplift in the skin price then SOH's decision to include the skin investment value in the profit and loss account means what was shown as a H1 profit contribution uplift of circa £13M (sp was over 63.5p 30th Jun 2021 when compared to 23.5p at 30th Dec 2020) will revert to a second half loss of some £3.7M allowing for the £2 cash contribution from the sale, when compared to H1 figures, effectively wiping out any trading figure progress in H2. So timing of the sale in advance of the end of year date hopefully has been done in expectation of good news from both companies before the year end

elrico, no offence taken just healthy debate. From what I can see, Croda International is just an umbrella for a number of divisions each made up of subsidiaries such as Sederma.

belgrano, only replying because elrico deemed it necessary to correct me and distinguish between the two and wrongly

elrico, re your comment that Croda manufacture it, I think you are mistaken on that. See Skin RNS 31 July 2020

"Cosmetic skincare

Sederma, the division of Croda Plc that specialises in the manufacture of bioactive ingredients for the cosmetic industry, has updated the Company on progress of its ongoing collaboration and confirmed that;


· Sederma has successfully replicated the lysate manufacturing process and achieved the same performance from the SkinBiotix® technology as established by the Company

· Sederma is now working to validate scale up of the manufacturing process at different volume levels

· The project is progressing in line with the original plan and has not been adversely impacted by COVID-19.

Sederma will be responsible for the development, manufacture and commercialisation of the SkinBiotix ® technology, with any products resulting from this programme being sold to Croda's global portfolio of Personal Care customers. SkinBioTherapeutics will be paid tiered royalties based on global sales revenues on any licensed products derived from the partnership."

Angoose, with junior miner investments, I don't go in for short term gains but take the chance that "truth drilling" comes up trumps and the company multi bags before the inevitable dip whilst waiting for production drilling to start. I didn't buy in at the highs but have added some at the new lows but not to a point where poor drill results would impact my overall portfolio too severely. Have also invested a similar amount in POW for the same reason but otherwise bulk of my investments are in other sectors.

July THIS year "date 6 drill holes have been completed successfully and safely at the Project, with 4 holes now assayed and all containing gold.

Overall, the assay results to date have delivered the outcome we were all hoping for, and I would like to put on record my thanks to Adam Jones, Dr. Rod Boucher and the drilling and core shed teams for their hard work that has delivered a considerable amount of data and information in a very short space of time. I look forward to reporting to the market with regard to further assay results, and their geological significance following analysis.”

Many thanks elrico

elrico, do we know for sure that the 20,000 litres final scale up has been achieved by Sederma; it is a pre-requisite for the Beauty Parade, and was anticipated to be completed by September according to the Business update?

Frustrating as it is Victoria has ben in lockdown delaying things like license application approvals and assays. This was posted by RRR in a RNS on 16th Nov

"Finally, the preparations for the IPO of our Australian assets located in the Victorian gold belt are continuing. As in West Africa, we used research to identify areas that could be picked up through new license applications, as this can be more cost-effective than purchase or farm-in. Having been fortunate in the timing of our initial applications in an area now in high demand, Covid-related measures in Victoria have slowed both grants and work since. The highly professional team on the ground in Australia have however used the extra time - that we would rather they had not had - this year to great effect in tracking old and forgotten mines and piecing together immediate drill targets that look prospective. As Victoria comes out of lockdowns activity by us and others will be increasing. We believe that we can find new mines in this nineteenth century gold rush territory and if we have the right management, enthusiasm, and money we shall do it quicker."

Link to the proactive investor interview for those that haven't seen it
https://www.youtube.com/watch?v=aPOBrx3c0A4
Between 34-38minutes in SOH talks about sweetbiotix, scaling up ourselves with a partner following translation from an open innovation project with Material Transfer Agreements to full commercial Agreement for beverages, dairy applications and snacks. "Quite a few discussions in place and whilst can't guarantee timings, pretty confident we'll get a number of large partner deals in H2". Hopefully, this is what the bulk of the money raised from the skin sale is earmarked for

Using an Agent or Distributor
U.S. companies are highly recommended to develop a local presence in India, whether through a branch office or a subsidiary or by appointing an agent, representative, or distributor. India is a diverse country, with over 30 regional languages and state-by-state differences in laws and regulations. A regional strategy ensures a wide market presence and greater flexibility in responding to regional demands and concerns. Income, purchasing power, educational attainment, and other socioeconomic factors vary greatly throughout India.

Furthermore, for products like pharmaceuticals, some medical devices, diagnostic kits, cosmetics, and food products, the Indian government may legally demand the appointment of an authorized agent or distributor. Quality assurance and standardization certificates are also required for some products (e.g., telecom equipment and home appliances). As a result, working with an agent, representative, or distributor who understands your target market and is familiar with local laws and policies, will help you expand your reach and increase your chances of success.
https://www.trade.gov/country-commercial-guides/india-distribution-and-sales-channels

Very true skid. That said, I see this as an added bonus which at least gives confidence that the strategic intent to move from ingredient supplier to significant end product sells, with their higher margins, can be delivered and in a huge market area. Good move.

Well about to make a small addition to my funds as promised 9445 shares to representing 94 days until the unaudited FY update due in Feb 2022 and 45 days to end H2 by which date we have been told to expect news on sweetbiotix; we shall see but my share purchase will be a constant reminder as to whether I have things right or wrong.

Relevant extract from the RRR Reach RNS re Australian Joint Venture for info

"Finally, the preparations for the IPO of our Australian assets located in the Victorian gold belt are continuing. As in West Africa, we used research to identify areas that could be picked up through new license applications, as this can be more cost-effective than purchase or farm-in. Having been fortunate in the timing of our initial applications in an area now in high demand, Covid-related measures in Victoria have slowed both grants and work since. The highly professional team on the ground in Australia have however used the extra time - that we would rather they had not had - this year to great effect in tracking old and forgotten mines and piecing together immediate drill targets that look prospective. As Victoria comes out of lockdowns activity by us and others will be increasing. We believe that we can find new mines in this nineteenth century gold rush territory and if we have the right management, enthusiasm, and money we shall do it quicker."

That is not what is inferred here Dazed. This will be used to grow the business not maintain the staus quo. What I would say is that listening to the presentation again, especially in relation to the second generation products and the progress made, I am really excited about the very near future and intend to add to my holdings. Expect news in the very near future re the scale up with a partner of sweetbiotix products which will see material transfer agreements move towards commercial agreements. Also, microbiome modulators, Opti have created a patented and unique process to take a probiotic and reverse engineer it to create a prebiotic to treat diseases. Scale-up has been an issue but late Spring this was cracked.
listen to the interview from 37.45 onwards for second gen products

If you listen to the investor meets presentation the answer to Q23 "SBTX - "assumes value returned to shareholders" - could you please expand on that?" confirms that no money will be paid as a dividend over the next 6 months (dated September).
Also, the money isn't required to keep the lights on looking at the Q&A to question 15.
"Q15: If Opti sign any of the contracts in H2 that could significantly impact on revenues (which were referred to in the last trading update), will the company likely need to raise any funds/sell sbtx shares to finance the purchase of stock/ingredients?

We will report our cash position in our interims so cannot disclose inside information. However, it hasn’t changed much from our 2020 end of year accounts cash position so currently are in a strong position and sales continue to grow. Our focus is on getting a number of deals with larger companies cross the line and the final commercial terms of these and timings of launches will determine any possible funding requirements."

There was no RNS for the previous sell in March 21 so no surprise this time

Belgrano, more importantly, we have been told that Opti's remaining 32,502,206 shares are locked in